Felodipine Tablet, Film Coated
Product Images NDC 72162-1742

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Felodipine (NDC 72162-1742). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (1 Formula)

Image Description (1 Formula)
Chemical structure of felodipine depicted as a molecular diagram showing its specific atomic and bonding arrangement, including chlorine atoms and ester groups.*
FDA Label Image

Label (Lbl721621742)

Label (Lbl721621742)
Label for Felodipine Extended-Release Tablets, USP, 2.5 mg strength. The label states the product contains 500 tablets and includes directions for storage and handling, emphasizing the tablets must be swallowed whole. The labeler is Bryant Ranch Prepack, with manufacturing by Yung Shin Pharmaceutical Ind. Co., Ltd. Both a barcode and QR code are present.*
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
A data table showing mean reductions in blood pressure (mmHg) from two studies of Felodipine tablets at various doses. The table details systolic/diastolic mean peak response, mean trough response, and trough/peak ratios (%). Study 1 presents results for 2.5 mg, 5 mg, and 10 mg doses over 8 weeks, while Study 2 shows data for 10 mg and 20 mg doses over 4 weeks, with a note that placebo response is subtracted and patient numbers vary for measurements.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
A data table showing the percent of patients experiencing various adverse events in controlled trials of Felodipine Extended-Release Tablets at doses of 2.5 mg, 5 mg, and 10 mg, compared to placebo. The table classifies adverse events by body system, with incidence and discontinuation rates in parentheses. It includes categories such as Body as a Whole, Cardiovascular, Digestive, Nervous, Respiratory, and Skin, listing specific symptoms and their occurrence percentages across different dose groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.